Cancer immunotherapy via nucleic acid aptamers.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Immunopharmacology

• Publication date

  2015-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.intimp.2015.10.013PMID 26603636
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

  2015cited by this paper
• Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers

  2015cited by this paper
• Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.

  2015cited by this paper
• Eosinophilic inflammation of chronic rhinosinusitis with nasal polyps is related to OX40 ligand expression

  2015cited by this paper
• The β-sitosterol attenuates atopic dermatitis-like skin lesions through down-regulation of TSLP

  2014cited by this paper
• Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Effect of tumor cells and tumor microenvironment on NK‐cell function

  2014cited by this paper
• New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization

  2014cited by this paper
• Development and Screening of a Series of Antibody‐Conjugated and Silica‐Coated Iron Oxide Nanoparticles for Targeting the Prostate‐Specific Membrane Antigen

  2014cited by this paper
• The role of mammalian target of rapamycin inhibitors in the management of post‐transplant malignancy

  2014cited by this paper
• Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.

  2014cited by this paper
• Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats

  2014cited by this paper
• Aptamer-targeted Antigen Delivery

  2014cited by this paper
• Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer.

  2013cited by this paper
• A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis

  2013cited by this paper
• CD28 Aptamers as Powerful Immune Response Modulators

  2013cited by this paper
• Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras.

  2013cited by this paper
• Immunotherapy of Cancer

  2012cited by this paper
• Isolation and Optimization of Murine IL-10 Receptor Blocking Oligonucleotide Aptamers Using High-throughput Sequencing.

  2012cited by this paper
• Aptamers and Their Biological Applications

  2012cited by this paper
• Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs

  2012cited by this paper
• Adoptive immunotherapy for cancer: harnessing the T cell response

  2012cited by this paper
• A novel aptamer targeting TGF-β receptor II inhibits transdifferentiation of human tenon's fibroblasts into myofibroblast.

  2012cited by this paper
• Cell-SELEX Technology

  2012cited by this paper
• Cancer immunotherapy via dendritic cells

  2012cited by this paper
• Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing.

  2012cited by this paper
• Prostate Cancer Immunotherapy by Targeting Dendritic Cells In Vivo Using Receptor-Specific Aptamer Conjugated to Prostate Stem Cell Antigen (PSCA)-Encoding RNA

  2011cited by this paper
• Cell-Specific Aptamers as Emerging Therapeutics

  2011cited by this paper
• Bi-specific Aptamers Mediating Tumor Cell Lysis

  2011cited by this paper
• Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• Beyond ipilimumab: new approaches target the immunological synapse.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.

  2010cited by this paper
• Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

  2010cited by this paper
• Aptamer-based electrochemical biosensor for interferon gamma detection.

  2010cited by this paper
• Development of DNA aptamers using Cell-SELEX

  2010cited by this paper
• Development of aptamer therapeutics.

  2010cited by this paper
• A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Costimulatory and coinhibitory receptors in anti‐tumor immunity

  2009cited by this paper
• The chemical biology of aptamers.

  2009cited by this paper
• The significance of OX40 and OX40L to T‐cell biology and immune disease

  2009cited by this paper
• Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

  2009cited by this paper
• Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors

  2009cited by this paper
• Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy

  2008cited by this paper
• Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule

  2008cited by this paper
• First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting

  2008cited by this paper
• Aptamers: molecular tools for analytical applications

  2008cited by this paper
• Aptamers in Immunotherapy

  2008cited by this paper
• Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice.

  2008cited by this paper
• Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-beta1 protein.

  2008cited by this paper
• Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer.

  2008cited by this paper
• Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

  2008cited by this paper
• Intracellular Signals of T Cell Costimulation

  2008cited by this paper
• Complex target SELEX.

  2008cited by this paper
• Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

  2007cited by this paper
• A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy.

  2007cited by this paper
• Binding of an aptamer to the N-terminal fragment of VCAM-1.

  2007cited by this paper
• Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.

  2007cited by this paper
• Cytotoxic T-Lymphocyte–Associated Antigen-4

  2007cited by this paper
• SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands.

  2007cited by this paper
• Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

  2007cited by this paper
• A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer

  2007cited by this paper
• Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

  2007cited by this paper
• Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

  2006cited by this paper
• Pharmacologic and Pharmacokinetic Assessment of Anti-TGFβ2 Aptamers in Rabbit Plasma and Aqueous Humor

  2006cited by this paper
• How many drug targets are there?

  2006cited by this paper
• Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

  2006cited by this paper
• Aptamer:toxin conjugates that specifically target prostate tumor cells.

  2006cited by this paper
• NY-ESO-1: review of an immunogenic tumor antigen.

  2006cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

  2005cited by this paper
• Conjugation to Polyethylene Glycol Polymer Promotes Aptamer Biodistribution to Healthy and Inflamed Tissues

  2005cited by this paper
• Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

  2005cited by this paper
• Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo

  2005cited by this paper
• Identification of potent and selective RNA antagonists of the IFN-gamma-inducible CXCL10 chemokine.

  2005cited by this paper
• Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt’s Lymphoma1

  2005cited by this paper
• Recombinant bispecific antibodies for cancer therapy

  2005cited by this paper
• Infection of lung epithelial cells and induction of pulmonary adenocarcinoma is not the most common outcome of naturally occurring JSRV infection during the commercial lifespan of sheep.

  2005cited by this paper
• clinical implications of basic research Shedding Light on Immunotherapy for Cancer

  2004cited by this paper
• SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1

  2004cited by this paper
• Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.

  2003cited by this paper
• Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

  2002cited by this paper
• Structural mechanisms of costimulation

  2002cited by this paper
• Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.

  2002cited by this paper
• 4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11

  2002cited by this paper
• Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells

  2001cited by this paper
• The generation and characterisation of antagonist RNA aptamers to MCP‐1

  2001cited by this paper
• In vitro selection of the RNA aptamer against the Sialyl Lewis X and its inhibition of the cell adhesion.

  2001cited by this paper
• Interleukin‐10 expressed at early tumour sites induces subsequent generation of CD4+ T‐regulatory cells and systemic collapse of antitumour immunity

  2001cited by this paper
• Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

  2000cited by this paper
• The Generation and Characterization of Antagonist RNA Aptamers to Human Oncostatin M*

  2000cited by this paper
• Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys.

  1999cited by this paper
• Liposome-anchored vascular endothelial growth factor aptamers.

  1998cited by this paper
• Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function.

  1998cited by this paper
• Oligonucleotide Inhibitors of P-Selectin-Dependent Neutrophil-Platelet Adhesion

  1998cited by this paper

• Oligonucleotide‐Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy

  2025cites this paper
• Aptamers as an approach to targeted cancer therapy

  2024cites this paper
• Aptamers combined with immune checkpoints for cancer detection and targeted therapy: A review.

  2024cites this paper
• The effect of redox bacteria on the programmed cell death-1 cancer immunotherapy

  2024cites this paper
• Application and Immunogenicity of Aptamers in Cancer Therapy

  2023cites this paper
• Label-free competitive time-resolved fluorescent aptasensor for the detection of Pb2+ using ssDNA-sensitized fluorescence of Tb3+ ions.

  2023cites this paper
• Fluorescent Chemo sensor nano-materials for Cancer bio-markers signalling: Towards development of non-invasive early detection strategies

  2023cites this paper
• Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy

  2023cites this paper
• Aptamers against cancer drug resistance: Small fighters switching tactics in the face of defeat.

  2023cites this paper
• Aptamer-Based Probes for Cancer Diagnostics and Treatment

  2022cites this paper
• Rapamycin attenuates gene expression of programmed cell death protein-ligand 1 and Foxp3 in the brain; a novel mechanism proposed for immunotherapy in the brain

  2021cites this paper
• Recent advances in aptamer-based nanosystems and microfluidics devices for the detection of ovarian cancer biomarkers

  2021cites this paper
• Potential applications of aptamers in veterinary science

  2021cites this paper
• Functional Immunostimulating DNA Materials: The Rising Stars for Cancer Immunotherapy.

  2021cites this paper
• Polysaccharide-based nanomedicines for cancer immunotherapy: A review

  2021cites this paper
• Functional Aptamer-Embedded Nanomaterials for Diagnostics and Therapeutics.

  2021cites this paper
• Discovery of tumoricidal DNA oligonucleotides by response-directed in vitro evolution

  2020cites this paper
• Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy.

  2020cites this paper
• Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs.

  2020cites this paper
• Aptamer-Mediated Nanotheranostics for Cancer Treatment: A Review

  2020cites this paper
• Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach

  2020cites this paper
• Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.

  2020cites this paper
• Discovery of tumoricidal DNA aptamers by effect-directed in-vitro evolution

  2019cites this paper
• Novel insights into the role of aptamers in the fight against cancer

  2019cites this paper
• Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer

  2019cites this paper
• Nanoparticles Advancing Cancer Immunotherapy

  2019cites this paper
• Therapeutic applications of AS1411 aptamer, an update review.

  2019cites this paper
• Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy.

  2018cites this paper
• Nucleic acids delivering nucleic acids

  2018cites this paper
• Nanoscale delivery systems for cancer immunotherapy

  2018cites this paper
• Antitumor immunity of DNA vaccine based on CTLA-4 fused with HER2 against colon carcinoma

  2018cites this paper
• Genetic Alphabet Expansion Provides Versatile Specificities and Activities of Unnatural-Base DNA Aptamers Targeting Cancer Cells

  2018cites this paper
• Current Advances in Aptamers for Cancer Diagnosis and Therapy

  2018cites this paper
• Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives

  2018cites this paper
• Functional‐DNA‐Driven Dynamic Nanoconstructs for Biomolecule Capture and Drug Delivery

  2018cites this paper
• ROS-Switchable Polymeric Nanoplatform with Stimuli-Responsive Release for Active Targeted Drug Delivery to Breast Cancer.

  2017cites this paper
• Recombination plasmid carrying hcg and survivin combination IL-12 generates specific immune responses and anti-tumor effects in a murine breast carcinoma model

  2017cites this paper
• Magnetic and fluorescent carbon nanotubes for dual modal imaging and photothermal and chemo-therapy of cancer cells in living mice

  2017cites this paper
• Structural optimization of an aptamer generated from Ligand-Guided Selection (LIGS) resulted in high affinity variant toward mIgM expressed on Burkitt's lymphoma cell lines.

  2017cites this paper
• Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

  2017cites this paper
• Advancement of the Emerging Field of RNA Nanotechnology

  2017cites this paper
• Fluorescence Sensing Using DNA Aptamers in Cancer Research and Clinical Diagnostics

  2017cites this paper
• Future strategies for the discovery of therapeutic aptamers

  2017cites this paper
• Chapter 3 Aptamers : Promising Molecules for Diagnosis and Treatment of Prostate Cancer

  2016cites this paper
• The increasingly anti-tumor effect of a colonic carcinoma DNA vaccine carrying HER2 by the adjuvanticity of IL-12

  2016cites this paper
• Cellular Delivery of RNA Nanoparticles.

  2016cites this paper
• Nucleic Acid Aptamers

  2016cites this paper
• Aptamers as targeted therapeutics: current potential and challenges

  2016cites this paper
• Trends in the Design and Development of Specific Aptamers Against Peptides and Proteins

  2016cites this paper